Details of the Drug Combinations

General Information of This Drug (ID: DM25HY3)

Drug Name
Ombrabulin   DM25HY3
Synonyms AVE8062
Indication
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

21 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Ombrabulin DC1FPAC 10-hydroxycamptothecin Hodgkin lymphoma (Cell Line: L-1236) [2]
ABT-263 + Ombrabulin DC8EUJD ABT-263 Hodgkin lymphoma (Cell Line: L-1236) [2]
AXL-1717 + Ombrabulin DC9XLOP AXL-1717 Ewing sarcoma (Cell Line: TC-71) [3]
Bardoxolone methyl + Ombrabulin DCDKWHB Bardoxolone methyl Hodgkin lymphoma (Cell Line: L-1236) [3]
Efaproxyn + Ombrabulin DCMW0RW Efaproxyn Ewing sarcoma (Cell Line: TC-71) [3]
Everolimus + Ombrabulin DCZUQ6M Everolimus Ewing sarcoma (Cell Line: TC-71) [3]
GDC-0084 + Ombrabulin DCODPCP GDC-0084 Hodgkin lymphoma (Cell Line: L-1236) [2]
JQ1 + Ombrabulin DCXI9F0 JQ1 Ewing sarcoma (Cell Line: TC-71) [3]
NVP-AUY922 + Ombrabulin DCR3Y3T NVP-AUY922 Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Buparlisib DCVIG6M Buparlisib Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Panobinostat DC4TYYU Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Ombrabulin + Everolimus DCAYIW0 Everolimus Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Lenvatinib DCDNEG8 Lenvatinib Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + AT7519 DCA1KXN AT7519 Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + OSI-906 DCS3ZB4 OSI-906 Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Vincristine DCD1GQD Vincristine Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Ispinesib DC5BHYM Ispinesib Ewing sarcoma (Cell Line: TC-71) [3]
Ombrabulin + Ruxolitinib DCDYIQV Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [2]
Ombrabulin + GDC-0084 DCTM69U GDC-0084 Hodgkin lymphoma (Cell Line: HDLM-2) [2]
Ombrabulin + GDC-0084 DCXZ69B GDC-0084 Hodgkin lymphoma (Cell Line: L-428) [2]
Panobinostat + Ombrabulin DCEXSTG Panobinostat Hodgkin lymphoma (Cell Line: L-1236) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 DrugCom(s)
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ombrabulin + Docetaxel DCO2EW2 Docetaxel Advanced Neoplastic Disease [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00699517) A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. U.S. National Institutes of Health.
2 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 ClinicalTrials.gov (NCT01907685) Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors